Early Palliative Care for Patients With Haematological Malignancies
NCT ID: NCT03800095
Last Updated: 2021-03-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE3
140 participants
INTERVENTIONAL
2019-03-14
2023-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Investigator did the hypothesis that early integration of palliative care with conventional haematological care could decrease discomfort symptoms and add a real benefit on the patients' quality of life .
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia
NCT05237258
A Collaborative Palliative and Oncology Care Model for Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome
NCT02975869
A Collaborative Palliative and Leukemia Care Model for Patients With AML and MDS Receiving Non-Intensive Therapy
NCT03310918
Expectations of Patients in Palliative Situation
NCT06786897
Feasibility of Telehealth Palliative Care and Digital Symptom Monitoring for Patients With Acute Myeloid Leukemia
NCT04885127
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Investigator did the hypothesis that early integration of palliative care with conventional haematological care could decrease discomfort symptoms and add a real benefit on the patients' quality of life .
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Conventional haematological care
Patients with haematological malignancy Conventional haematological care
Early palliative care integration
The follow-up time for each patient is 12 months with evaluation of the main objective by a standardized questionnaire: The Functional Assessment of Cancer Therapy-Anaemia (FACT-An) Scale at 6 months. Throughout the study, patients included will receive conventional haematological care and the interventional arm will benefit in addition to a monthly consultation by a palliative care team.
Conventional care associated with a monthly consultation
Patients with haematological malignancy Conventional care associated with a monthly consultation realized by a palliative and supportive care team
Early palliative care integration
The follow-up time for each patient is 12 months with evaluation of the main objective by a standardized questionnaire: The Functional Assessment of Cancer Therapy-Anaemia (FACT-An) Scale at 6 months. Throughout the study, patients included will receive conventional haematological care and the interventional arm will benefit in addition to a monthly consultation by a palliative care team.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Early palliative care integration
The follow-up time for each patient is 12 months with evaluation of the main objective by a standardized questionnaire: The Functional Assessment of Cancer Therapy-Anaemia (FACT-An) Scale at 6 months. Throughout the study, patients included will receive conventional haematological care and the interventional arm will benefit in addition to a monthly consultation by a palliative care team.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients from being diagnosed with acute myeloid leukemia and high-risk myelodysplastic syndrome or after the third line of therapy for high-grade lymphoma.
Exclusion Criteria
* All patients in a terminal palliative status
* Patients who don't speak French,
* Patients not able to read and write
* Patients who don't agree to participate in the protocol
* Patients with psychiatric troubles or cognitive disorders
* Patients under guardianship or curatorship, deprived of freedom or under justice protection.
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Fondation Apicil
OTHER
Association des foulées de la Haute Lozère
UNKNOWN
Association CEMSBM
UNKNOWN
Connaître et Combattre les Myélodysplasies
UNKNOWN
University Hospital, Clermont-Ferrand
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Centre Hospitalier Métropole Savoie
Chambéry, , France
Chu Clermont-Ferrand
Clermont-Ferrand, , France
Chu Limoges
Limoges, , France
Centre Léon Bérard
Lyon, , France
Institut de Cancérologie de la Loire
Saint-Priest-en-Jarez, , France
CH Jacques Lacarin
Vichy, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Laurent SUTTON
Role: primary
Stéphane MOREAU
Role: primary
Anne-Sophie MICHALLET
Role: primary
Denis GUYOTAT
Role: primary
Karine SOULIER-GUERIN
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2017-A02515-48
Identifier Type: OTHER
Identifier Source: secondary_id
CHU-406
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.